Ph 1/2 Program Initiated for Elraglusib in refractory melanoma and additional target solid tumor and heme cancers
“With the promising results we have seen with the IV formulation of elraglusib across an array of difficult-to-treat cancers, we are excited to advance the oral tablet formulation in additional indications, including patients with R/R metastatic melanoma,” said Dan Schmitt, Chief Executive Officer of Actuate Therapeutics. “Elraglusib oral tablet will allow us to further explore elraglusib dose using a convenient and easily administered tablet dosage form that will be amenable to evaluation as a single agent. The program builds on encouraging results from our phase 1 monotherapy clinical trial with the IV formulation, including a remarkable complete response lasting more than 6 years from a patient with highly advanced, highly disseminated, refractory BRAFV600E-mutated metastatic melanoma. We believe the elraglusib oral tablet will have the potential to play an important role in addressing a significant unmet need in the treatment of refractory melanoma as well as other advanced cancer indications.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines